...
itos-img

Iteos Therapeutics Inc, Common Stock

ITOS

NMQ

$7.225

-$0.04

(-0.55%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$280.95M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
58.22K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.39
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$7.13 L
$18.75 H
$7.225

About Iteos Therapeutics Inc, Common Stock

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc"R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameITOSSectorS&P500
1-Week Return-12.53%-3.39%-3.47%
1-Month Return-7.87%-3.25%-0.29%
3-Month Return-37.36%-11.61%4.5%
6-Month Return-51.44%-5.89%6.91%
1-Year Return-32.09%2.65%23.79%
3-Year Return-83.25%0.56%28.43%
5-Year Return-61.89%34.63%83.64%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue--344.77M267.63M12.60M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":77.62,"profit":true},{"date":"2023-12-31","value":3.65,"profit":true}]
Cost of Revenue611.00K535.00K615.00K813.00K898.00K[{"date":"2019-12-31","value":68.04,"profit":true},{"date":"2020-12-31","value":59.58,"profit":true},{"date":"2021-12-31","value":68.49,"profit":true},{"date":"2022-12-31","value":90.53,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(611.00K)(535.00K)344.16M266.82M11.70M[{"date":"2019-12-31","value":-0.18,"profit":false},{"date":"2020-12-31","value":-0.16,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":77.53,"profit":true},{"date":"2023-12-31","value":3.4,"profit":true}]
Gross Margin--99.82%99.70%92.87%[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.87,"profit":true},{"date":"2023-12-31","value":93.04,"profit":true}]
Operating Expenses23.27M39.31M89.69M138.04M163.70M[{"date":"2019-12-31","value":14.21,"profit":true},{"date":"2020-12-31","value":24.01,"profit":true},{"date":"2021-12-31","value":54.79,"profit":true},{"date":"2022-12-31","value":84.33,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(28.05M)(45.24M)244.90M126.32M(151.10M)[{"date":"2019-12-31","value":-11.45,"profit":false},{"date":"2020-12-31","value":-18.47,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":51.58,"profit":true},{"date":"2023-12-31","value":-61.7,"profit":false}]
Total Non-Operating Income/Expense5.71M-11.64M33.77M72.97M[{"date":"2019-12-31","value":7.83,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":15.95,"profit":true},{"date":"2022-12-31","value":46.28,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(22.34M)(38.09M)256.46M148.74M(109.03M)[{"date":"2019-12-31","value":-8.71,"profit":false},{"date":"2020-12-31","value":-14.85,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":57.99,"profit":true},{"date":"2023-12-31","value":-42.51,"profit":false}]
Income Taxes119.00K(57.00K)41.94M52.08M3.61M[{"date":"2019-12-31","value":0.23,"profit":true},{"date":"2020-12-31","value":-0.11,"profit":false},{"date":"2021-12-31","value":80.53,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":6.93,"profit":true}]
Income After Taxes(22.45M)-214.52M96.65M(112.64M)[{"date":"2019-12-31","value":-10.47,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":45.05,"profit":true},{"date":"2023-12-31","value":-52.51,"profit":false}]
Income From Continuous Operations(22.45M)(38.03M)214.52M96.65M(61.64M)[{"date":"2019-12-31","value":-10.47,"profit":false},{"date":"2020-12-31","value":-17.73,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":45.05,"profit":true},{"date":"2023-12-31","value":-28.73,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(22.45M)(38.03M)214.52M96.65M(112.64M)[{"date":"2019-12-31","value":-10.47,"profit":false},{"date":"2020-12-31","value":-17.73,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":45.05,"profit":true},{"date":"2023-12-31","value":-52.51,"profit":false}]
EPS (Diluted)-(30.82)5.612.56(3.15)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-549.29,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":45.63,"profit":true},{"date":"2023-12-31","value":-56.15,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ITOS
Cash Ratio 13.28
Current Ratio 14.80

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ITOS
ROA (LTM) -13.04%
ROE (LTM) -19.72%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ITOS
Debt Ratio Lower is generally better. Negative is bad. 0.13
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.87

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ITOS
Trailing PE NM
Forward PE 12.56
P/S (TTM) 8.03
P/B 0.45
Price/FCF NM
EV/R 1.26
EV/Ebitda 0.50

FAQs

What is Iteos Therapeutics Inc share price today?

Iteos Therapeutics Inc (ITOS) share price today is $7.225

Can Indians buy Iteos Therapeutics Inc shares?

Yes, Indians can buy shares of Iteos Therapeutics Inc (ITOS) on Vested. To buy Iteos Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ITOS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Iteos Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Iteos Therapeutics Inc (ITOS) via the Vested app. You can start investing in Iteos Therapeutics Inc (ITOS) with a minimum investment of $1.

How to invest in Iteos Therapeutics Inc shares from India?

You can invest in shares of Iteos Therapeutics Inc (ITOS) via Vested in three simple steps:

  • Click on Sign Up or Invest in ITOS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Iteos Therapeutics Inc shares
What is Iteos Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Iteos Therapeutics Inc (ITOS) is $18.75. The 52-week low price of Iteos Therapeutics Inc (ITOS) is $7.13.

What is Iteos Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Iteos Therapeutics Inc (ITOS) is

What is Iteos Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Iteos Therapeutics Inc (ITOS) is 0.45

What is Iteos Therapeutics Inc dividend yield?

The dividend yield of Iteos Therapeutics Inc (ITOS) is 0.00%

What is the Market Cap of Iteos Therapeutics Inc?

The market capitalization of Iteos Therapeutics Inc (ITOS) is $280.95M

What is Iteos Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Iteos Therapeutics Inc is ITOS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top